I keep wondering if this is a potential risk for BETonMACE.
The primary endpoint is the Time to the first occurrence of Major Adverse Cardiovascular Events (MACE).
Could this be a problem? Does it help us to meet the endpoint or not? Because, the way I see RRR calculated here is with events. 150 events on placebo, 100 on ABL, 33% RRR. Fine. But thats juste relative events on each side. Is no events = x amount of time on the trial? Will just people that had an event will count on the RRR calculation?
Maybe I missed something.